COR Cencora Inc

Cencora (formerly AmerisourceBergen) is one of the world's largest pharmaceutical distribution companies, serving health systems, retail pharmacies, and specialty medical practices. Sector: Healthcare.

Cencora Inc (COR) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Examining the company through a capital allocation lens, ROIC is 17.66%, WACC is 6.77%, and the economic spread is 10.89%. On balance, the spread between ROIC and WACC is solidly positive — reinvestment is adding value rather than diluting it. Supporting metrics show ROE at 118.53% and ROA at 3.42%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

Valuation currently screens at trailing P/E of 20.40, forward P/E of 14.61, PEG of 1.39. Trailing and forward multiples are somewhat apart, indicating the market is pricing measured earnings growth without aggressive expansion assumptions. A PEG below 1.5 implies the company's growth rate is not fully reflected in the current multiple — a constructive signal for growth-adjusted value. The aggregate current ratio of 0.95 reflects tighter near-term liquidity — a factor worth monitoring if macro conditions tighten. The valuation profile here is neither obviously cheap nor dramatically expensive — a setup where the return case is built more on earnings delivery than on re-rating potential.

From gross to free cash flow, gross margin sits at 3.81%, operating margin at 1.30%, and free cash flow margin at 0.47%. At this level, gross margins signal that pricing power is constrained and direct cost management is a key performance driver. At this level, operating margins signal that earnings quality is limited — a feature of growth-stage or restructuring businesses. The company's FCF margin signals that most revenue is being consumed before reaching the free cash flow line — a feature of early-stage or heavily invested businesses. The margin profile is mixed, with some layers more resilient than others and less room for execution slippage.

Combining revenue momentum with analyst targets, the estimated 12-month price change of 34.70%, where analysts are collectively positioned for a material move higher, while TTM revenue growth of 3.85% indicating muted but still positive top-line momentum across the company. Separating operating reality from market-implied expectations is useful here — they can diverge meaningfully when sentiment shifts. The forward return case hinges on whether the operating reality stays close enough to analyst assumptions for those targets to remain credible. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

When all the evidence is placed side by side, this profile stands out as one with genuine compounding characteristics and limited structural headwinds.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.